FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Sprint Nerve Stimulator Gains Broader Indication

FDA clears an SPR Therapeutics 510(k) for a broader indication for use for its Sprint Peripheral Nerve Stimulation System head, neck, and the front o...

Human Drugs

Oyster Point Nasal Spray for Dry Eye OKd

FDA approves an Oyster Point Pharma NDA for Tyrvaya (varenicline solution) nasal spray 0.03 mg for treating signs and symptoms of dry eye disease.

FDA Warns 2 Physician Researchers

FDA warns two Hennepin County Medical Center researchers they failed to submit INDs for their clinical investigations.

FDA General

Sen. Blumenthal Likely to Oppose Califf Nomination

Sen. Richard Blumenthal (D-CT) tells a Bloomberg News reporter that he will likely oppose Duke University School of Medicine professor Robert Califfs ...

Human Drugs

CGMP Deviations at Marcus Research Laboratory

FDA warns Marcus Research Laboratory about CGMP deviations in its production of active pharmaceutical ingredients.

Biologics

Revance BLA Shot Down Over Inspection Findings

FDA sends Revance Therapeutics a complete response letter on its BLA for daxibotulinumtoxinA for Injection, indicated for treating frown lines, due to...

Human Drugs

Complete Response on Stem Cell Transplant Therapy

FDA issues Omeros a complete response letter on its BLA for narsoplimab as a treatment for hematopoietic stem cell transplant-associated thrombotic mi...

Human Drugs

IRB Review Needed for all IVD Studies: FDA

FDA reminds in vitro diagnostic manufacturers that the agency requires an institutional review board review for all device clinical investigations tha...

Human Drugs

United Therapeutics Snubbed on Tyvaso DPI

United Therapeutics receives an FDA complete response letter on its NDA for Tyvaso DPI (treprostinil) for treating pulmonary arterial hypertension and...

Biologics

Boehringers Humira Biosimilar Now Interchangeable

FDA approves a Boehringer Ingelheim supplemental BLA for Cyltezo (adalimumab-adbm), an interchangeablebiosimilar that will allow pharmacy substitution...